Related Experiment Videos
Potential neuroprotective therapy for glaucomatous optic neuropathy
1Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel.
Survey of Ophthalmology
|March 11, 1998
Summary
Secondary degeneration causes glaucoma progression even after pressure reduction. Neuroprotection strategies are needed to shield healthy neurons from this spread, using animal models to test new therapies.
Area of Science:
- Neuroscience
- Ophthalmology
Background:
- Glaucomatous neuropathy progression persists despite reduced intraocular pressure.
- Secondary degeneration, the spread of damage to healthy neurons near injured ones, is a proposed mechanism.
- This spread is driven by a degenerative environment created by the initial injury.
Purpose of the Study:
- To investigate the mechanism of secondary degeneration in glaucomatous neuropathy.
- To develop and utilize an animal model for studying neuroprotection against secondary degeneration.
- To evaluate the potential for neuroprotective therapies in glaucoma treatment.
Main Methods:
- Developed a reproducible rat optic nerve partial lesion model.
- Quantified primary optic nerve damage.
- Assessed secondary degeneration in initially spared neurons over time.
Main Results:
- Optic nerve damage leads to secondary degeneration of adjacent neurons.
- The extent of secondary degeneration correlates with the severity of the primary insult.
- The animal model demonstrated and assessed secondary degeneration effectively.
Conclusions:
- Secondary degeneration may explain ongoing glaucoma damage after primary cause treatment.
- Neuroprotection is crucial for preserving vision in glaucoma patients.
- The developed model supports the development of combined neuroprotective and pressure-lowering therapies for glaucoma.